Browsing by Author "Türkmen, M"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
    Gönülal, M; Altunay, IK; Dogan, S; Türkmen, M; Balci, DD; Öztürkcan, S
    Real-life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL-17 antagonist ixekizumab. This study was designed as a retrospective multi-center study. Four tertiary referral centers participated into the study. The patients who did not present to the clinics for 3rd month follow-up were excluded. Data including gender, age, weight, type of psoriasis, additional sites on the body, disease duration, previous treatments, duration of medication of ixekizumab, psoriasis area and severity index scores, previous treatments, and comorbidities, the reasons for drug discontinuation, adverse effects and the patients' naive or non-naive status were retrieved from electronic patient folders. Although 267 patients met the inclusion criteria, 28 patients were excluded since they did not present to the clinic for 3rd month follow-up so 239 cases were included mmune research. We determined significant correlations between naive and non-naive cases about getting PASI 75 and PASI 90 responses for all cases (p = 0.005 and p = 0.028, respectively) and between comorbid and non-comorbid cases about getting PASI 90 and PASI 100 responses for all cases (p = 0.021 and p = 0.029, respectively). When we investigate as female and male patients separately, non-comorbid female cases can achieve PASI 100 response significantly easier than comorbid female patients (p = 0.019). Clinicians can use ixekizumab safely mmune treatment of their patients with psoriasis and get PASI 75-90-100 responses quickly. Ixekizumab is more effective for naive cases but it may also be a treatment option for biologic experienced patients. The ratio of PASI 75-90-100 responses are better in non-comorbid cases than comorbid patients nevertheless ixekizumab is a quite effective agent mmune treatment of comorbid cases.
  • No Thumbnail Available
    Item
    Modification of the radial beam port of ITU TRIGA Mark II research reactor for BNCT applications
    Akan, Z; Türkmen, M; Çakir, T; Reyhancan, IA; Çolak, Ü; Okka, M; Kiziltas, S
    This paper aims to describe the modification of the radial beam port of ITU (Istanbul Technical University) TRIGA Mark II research reactor for BNCT applications. Radial beam port is modified with Polyethylene and Cerrobend collimators. Neutron flux values are measured by neutron activation analysis (Au-Cd foils). Experimental results are verified with Monte Carlo results. The results of neutron/photon spectrum, thertnal/epithermal neutron flux, fast group photon fluence and change of the neutron fluxes with the beam port length are presented. (C) 2015 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    The natural history study of hidradenitis suppurativa: A large-scale multicenter study in turkey
    Alpsoy, E; Karaman, BF; Demirseren, D; Cinar, L; Kacar, N; Ermertcan, AT; Baskan, EB; Ucmak, D; Mammadli, K; Kilinç, F; Yazici, S; Temiz, SA; Akbulut, TÖ; Ataseven, A; Aktürk, AS; Saricaoglu, H; Türkmen, M; Gülbasaran, F; Engin, B; Ozden, HK; Durmaz, K; Ozden, MG; Ozdemir, H; Cemil, BC; Solak, SS; Yavuz, IH; Yavuz, GO; Guven, M; Ekinci, AP; Atici, T; Balci, DD; Oztürk, A; Altunay, IK; Ozkur, E; Ugurer, E; Karadag, AS; Kalkan, G; Erdogan, B; Yayli, S; Selcuk, LB; Donmez, L; Bilgic, A
  • No Thumbnail Available
    Item
    Clinical Features and Natural Course of Hidradenitis Suppurativa in Turkey: A Multicenter Study
    Alpsoy, E; Karaman, BF; Demirseren, DD; Cinar, SL; Kacar, N; Ermertcan, AT; Baskan, EB; Ucmak, D; Mammadli, K; Kilinc, F; Yazici, S; Temiz, SA; Akbulut, TO; Ataseven, A; Aktürk, AS; Saricaoglu, H; Türkmen, M; Gülbasaran, F; Engin, B; Özden, HK; Durmaz, K; Özden, MG; Özdemir, H; Cemil, BÇ; Solak, SS; Bilgili, SG; Yavuz, IH; Yavuz, GÖ; Güven, M; Ekinci, AP; Atci, T; Balci, DD; Oztürk, A; Altunay, IK; Özkur, E; Ugurer, E; Karadag, AS; Kalkan, G; Kilic, S; Erdogan, B; Yayli, S; Selcuk, LB; Dönmez, L; Bilgic, A
    Introduction:The natural history, the progression of a diseaseprocess in an individual over time, has not yet been fully elu-cidated in hidradenitis suppurativa (HS). In this large multicenterstudy, we aimed to investigate the natural history of HS and itsgender differences.Methods:This cross-sectional study in-cluded 827 patients. The chronological order of the clinicalmanifestations for each patientwas recorded retrospectively.Sociodemographic characteristics, triggering factors, clinical,treatment, and prognostic features were also evaluated.Results:The mean age of disease onset was significantly younger inwomen than in men (22.42 +/- 9.28 vs. 27.06 +/- 20.56,p<0.001)and those with a family history (p<0.0001). The mean diseaseduration was 91.17 +/- 83.64 months. The most commonsymptom was purulent discharge (81%). The mean duration ofabscess was shorter in women than in men (3.11 +/- 2.65 vs.3.75 +/- 3.75,p= 0.01). The axilla was the most common onsetarea followed by the inguinal and gluteal regions. The diseaseran a more severe course in men. Abscess/inflammatory nodulewas defined in the last 6 months in 88.6% of the patients;however, thefirst 5 years of the disease were the most activedisease period in 67.5% of the patients. Multivariate analysisrevealed being male, older age, family history, involvement ofthe axillary, inguinal, and perianal regions independently as-sociated with HS severity. While antibiotic use was the mostimportant factor in improving thedisease symptoms, stress wasthe most common aggravating factor. Biological therapy in men,laser epilation and pregnancy in women were significant alle-viating factors, whereas weight gain was a more commonaggravating factor for women.Conclusion:HS shows a re-lentlessly progressive course with inflammatory attacks, but thefirst years of the disease are the most active period. This studyconfirms that environmental and hormonal factors may play animportant role in the disease course, probably with other en-dogenous or exogenous factors.(c) 2024 S. Karger AG, Basel
  • No Thumbnail Available
    Item
    Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity
    Özkur, E; Karadag, AS; Üstüner, P; Aksoy, B; Esme, P; Çaliskan, E; Akoglu, G; Kalkan, G; Demirseren, DD; Polat, M; Ozden, MG; Kilinç, F; Iyidal, AY; Altunay, IK; Türkmen, M; Ugurer, E; Baysak, S; Karaman, BF; Mammadli, K; Selçuk, LB; Türkoglu, Z; Atci, T; Balci, DD; Adisen, E; Temel, B; Aktan, S; Kaçar, N; Gündüz, K; Ertmertcan, AT; Özdemir, M; Çakiter, AÜ; Çölgeçen, E; Uçmak, D; Kelekçi, H; Ataseven, A; Durmaz, K; Özden, HK; Engin, B; Yazici, S; Alpsoy, E
    Background Hidradenitis suppurativa (HS) is a chronic, relapsing and debilitating inflammatory disease associated with profound morbidity. Aim In this multicentre study, we investigated the demographic and clinical features of HS, and determined risk factors of disease severity. Methods In total, 1221 patients diagnosed with HS from 29 centres were enrolled, and the medical records of each patient were reviewed. Results The mean age of disease onset was 26.2 +/- 10.4 years, and almost 70% (n = 849) of patients were current or former smokers. Mean disease duration was 8.9 +/- 8.4 years with a delay in diagnosis of 5.8 +/- 3.91 years. Just over a fifth (21%; n = 256) of patients had a family history of HS. The axillary, genital and neck regions were more frequently affected in men than in women, and the inframammary region was more frequently affected in women than in men (P < 0.05 for all). Acne (40.8%), pilonidal sinus (23.6%) and diabetes mellitus (12.6%) were the most prevalent associated diseases. Of the various therapies used, antibiotics (76.4%) were most common followed by retinoids (41.7%), surgical interventions (32.0%) and biologic agents (15.4%). Logistic regression analysis revealed that the most important determinants of disease severity were male sex (OR = 2.21) and involvement of the genitals (OR = 3.39) and inguinal region (OR = 2.25). More severe disease was associated with comorbidity, longer disease duration, longer diagnosis delay and a higher number of smoking pack-years. Conclusions Our nationwide cohort study found demographic and clinical variation in HS, which may help broaden the understanding of HS and factors associated with disease severity.